Product Information
BREO ELLIPTA 100-25 MCG INHALR is a brand product labeled by GlaxoSmithKline LLC, priced at $6.4989 per EA under NDC 00173085910. Its NADAC has been published 668 times since Dec 18, 2013.
FDA first approved this application on May 10, 2013.
Strength
100; 25 ug/1; ug/1
Manufacturer
GlaxoSmithKline LLCNDC
00173085910
Classification
Brand
Dosage Form
POWDER
Route
RESPIRATORY (INHALATION)
Effective Date
9/23/2026
Active Ingredients
FLUTICASONE FUROATE; VILANTEROL TRIFENATATEApproval Type
New Drug (NDA)
FDA Application
NDA204275FDA Approved
5/10/2013
On Market Since
8/26/2013
Pharmacological Classes
Price Statistics
The NADAC for BREO ELLIPTA 100-25 MCG INHALR has been published 668 times since Dec 18, 2013, and over the history we have for it it has risen 54.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $6.4989 per EA |
|---|---|
| All-time high | $6.5151 (Aug 14, 2024) |
| All-time low | $4.1970 (Dec 18, 2013) |
| 52-week high | $6.5080 |
| 52-week low | $6.4989 |
| Median price | $5.7858 |
| Average price | $5.6286 |
| Largest weekly change | +8.0% (Jan 11, 2017) |
| Weeks tracked | 668 |
| Tracking since | Dec 18, 2013 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 18% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
GlaxoSmithKline LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
fluticasone furoate and vilanterol trifenatate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Corticosteroid class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of BREO ELLIPTA 100-25 MCG INHALR?
The current National Average Drug Acquisition Cost (NADAC) for BREO ELLIPTA 100-25 MCG INHALR, manufactured by GlaxoSmithKline LLC, is $6.4989 per EA (NDC 00173085910), effective Sep 30, 2026.
How has the price of BREO ELLIPTA 100-25 MCG INHALR changed over time?
Over the history we have for it, the NADAC for BREO ELLIPTA 100-25 MCG INHALR has risen 54.8%. It has been tracked across 668 weekly CMS publications since Dec 18, 2013.
What are the highest and lowest recorded NADAC prices for BREO ELLIPTA 100-25 MCG INHALR?
Since Dec 18, 2013, the NADAC for BREO ELLIPTA 100-25 MCG INHALR has ranged from a low of $4.1970 (Dec 18, 2013) to a high of $6.5151 (Aug 14, 2024), with a median of $5.7858 per EA.
Are there cheaper alternatives to BREO ELLIPTA 100-25 MCG INHALR?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, BREO ELLIPTA 100-25 MCG INHALR, is $5.3610 per EA — about 18% below BREO ELLIPTA 100-25 MCG INHALR.
Who manufactures BREO ELLIPTA 100-25 MCG INHALR?
BREO ELLIPTA 100-25 MCG INHALR (NDC 00173085910) is labeled by GlaxoSmithKline LLC, and CMS classifies it as a brand product.